GGrantIndex
← Search

MOLECULAR BIOLOGY AND GENETICS

$0P30FY2001CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

Description: (Applicant's Description) The Molecular Biology and Genetics Program is focused on the utilization of genomic information from studies of organisms from yeast to man in the discovery and functional analysis of novel genes responsible for cancer predisposition in "high risk" populations as well as in sporadic cancers. Cancer development is associated with a series of changes in cellular genes. These changes occur as mutations or variations in gene expression in cancer causing genes and in other genes which respond to them. These genetic alterations provide molecular signatures specific to each tumor type. Cancer susceptibility genes frequently cause so-called "genomic instability" in which cells develop DNA damage in critical cancer-causing genes such as oncogenes and tumor suppressor genes. Both germline or somatic mutations affect proteins involved in signal transduction such as growth factor receptor pathways or transcription factors leading to changes in gene expression. Studies in human populations at extreme risk to cancer can be applied to the general population in which the genetics of cancer risk is more subtle. The current efforts of this program are on mechanisms of genomic instability, chromatin structure, cell cycle checkpoint control, transcriptional regulation of signal transduction, and post-translational control mechanisms. We utilize cell lines and whole animals to model the genetic mechanisms leading to precancerous cells, the molecular signatures of precancerous lesions, and the critical genetic events in the progression of these cells to neoplasia. Because of the extensive body of genetic information on DNA repair genes and growth control mechanisms in model organisms, we are applying the genetics of yeast and mouse model systems to understand human gene structure and function. We are analyzing the human homologues of well characterized yeast DNA repair and checkpoint genes for their role in genetic and sporadic human cancers. These genetic mechanisms will provide useful molecular targets for cancer detection, chemoprevention and chemotherapy. This body of knowledge also provides a novel approach to cancer risk determination in special populations available in the patient base associated with the Karmanos Cancer Institute.

View original record on NIH RePORTER →